DNDI-VL-2098 | CAS#unknown | Visceral Leishmaniasis inhibitor

MedKoo Cat#: 463911 | Name: DNDI-VL-2098

Description:

WARNING: This product is for research use only, not for human or veterinary use.

DNDI-VL-2098 is a visceral leishmaniasis inhibitor.

Chemical Structure

DNDI-VL-2098

CAS#unknown

Theoretical Analysis

MedKoo Cat#: 463911

Name: DNDI-VL-2098

CAS#: unknown

Chemical Formula: C14H12F3N3O5

Exact Mass: 359.0729

Molecular Weight: 359.26

Elemental Analysis: C, 46.81; H, 3.37; F, 15.86; N, 11.70; O, 22.27

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

DNDI-VL-2098; DNDIVL-2098; DNDI VL-2098; DNDI-VL2098; DNDI-VL 2098; DNDIVL2098; DNDI VL 2098;

IUPAC/Chemical Name

(R)-2-methyl-6-nitro-2-((4-(trifluoromethoxy)phenoxy)methyl)-2,3-dihydroimidazo[2,1-b]oxazole

InChi Key

GPWIINYCHXCGQH-CYBMUJFWSA-N

InChi Code

InChI=1S/C14H12F3N3O5/c1-13(7-19-6-11(20(21)22)18-12(19)25-13)8-23-9-2-4-10(5-3-9)24-14(15,16)17/h2-6H,7-8H2,1H3/t13-/m1/s1

SMILES Code

C[C@]1(COC2=CC=C(OC(F)(F)F)C=C2)CN3C(O1)=NC([N+]([O-])=O)=C3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 359.26 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Patel BD, Uppal R, Pulakundam N, Patel JP, Ramanathan V, Ameta R, Launay D, Braillard S. Development and validation of LC-MS/MS method for determination of DNDI-VL-2098 in mouse, rat, dog and hamster blood. Bioanalysis. 2019 Aug;11(15):1419-1435. doi: 10.4155/bio-2019-0128. PMID: 31490107. 2: Satam VS, Pedada SR, Kamaraj P, Antao N, Singh A, Hindupur RM, Pati HN, Thompson AM, Launay D, Martin D. Development of a Scalable Process for the Synthesis of DNDI-VL-2098: A Potential Preclinical Drug Candidate for the Treatment of Visceral Leishmaniasis. Org Process Res Dev. 2017 Jan 20;21(1):52-59. doi: 10.1021/acs.oprd.6b00331. Epub 2016 Dec 6. PMID: 28539754; PMCID: PMC5437808. 3: Thompson AM, O'Connor PD, Marshall AJ, Yardley V, Maes L, Gupta S, Launay D, Braillard S, Chatelain E, Franzblau SG, Wan B, Wang Y, Ma Z, Cooper CB, Denny WA. 7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis. J Med Chem. 2017 May 25;60(10):4212-4233. doi: 10.1021/acs.jmedchem.7b00034. Epub 2017 May 11. PMID: 28459575; PMCID: PMC7722354. 4: Wyllie S, Roberts AJ, Norval S, Patterson S, Foth BJ, Berriman M, Read KD, Fairlamb AH. Activation of Bicyclic Nitro-drugs by a Novel Nitroreductase (NTR2) in Leishmania. PLoS Pathog. 2016 Nov 3;12(11):e1005971. doi: 10.1371/journal.ppat.1005971. PMID: 27812217; PMCID: PMC5094698. 5: Thompson AM, O'Connor PD, Blaser A, Yardley V, Maes L, Gupta S, Launay D, Martin D, Franzblau SG, Wan B, Wang Y, Ma Z, Denny WA. Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis. J Med Chem. 2016 Mar 24;59(6):2530-50. doi: 10.1021/acs.jmedchem.5b01699. Epub 2016 Mar 8. PMID: 26901446. 6: Gupta S, Yardley V, Vishwakarma P, Shivahare R, Sharma B, Launay D, Martin D, Puri SK. Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis. J Antimicrob Chemother. 2015 Feb;70(2):518-27. doi: 10.1093/jac/dku422. Epub 2014 Nov 10. PMID: 25389223. 7: Mukkavilli R, Pinjari J, Patel B, Sengottuvelan S, Mondal S, Gadekar A, Verma M, Patel J, Pothuri L, Chandrashekar G, Koiram P, Harisudhan T, Moinuddin A, Launay D, Vachharajani N, Ramanathan V, Martin D. In vitro metabolism, disposition, preclinical pharmacokinetics and prediction of human pharmacokinetics of DNDI-VL-2098, a potential oral treatment for Visceral Leishmaniasis. Eur J Pharm Sci. 2014 Dec 18;65:147-55. doi: 10.1016/j.ejps.2014.09.006. Epub 2014 Sep 27. PMID: 25261338.